Talaris Therapeutics, a privately held biotechnology company developing transformative cell therapies that have the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients, announced the initiation of FREEDOM-1, the company’s Phase 3 clinical trial of FCR001 in living donor kidney transplant (LDKT) recipients.
Cyclo Therapeutics, formerly CTD Holdings, a biotechnology company that develops cyclodextrin-based products for the treatment of disease, announced that it has completed patient enrollment in its Phase I trial to evaluate the safety and tolerability of Trappsol Cyclo administered intravenously to Niemann-Pick Disease Type C (NPC) patients.
Odonate Therapeutics, a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced the completion of enrollment in CONTESSA, a multinational, multicenter, randomized, Phase 3 study investigating tesetaxel as a potential treatment for patients with HER2 negative, hormone receptor positive metastatic breast cancer.
Trial to evaluate the effectiveness of KRYSTEXXA to sustain reduced serum uric acid levels for post-kidney transplant adults; a vulnerable population.
Boehringer Ingelheim announced the first patient enrolled in its Phase II clinical trial BALANCE-CFTM 1 to evaluate a new potential treatment for cystic fibrosis.
Trialbee, a world-leading technology provider in patient matching and engagement, is partnering with TriNetX, a leading global real-world health research network comprised of >170M patients across 23 countries to support data-driven digital solutions to accelerate patient-centric clinical trials.
Forbius, a clinical-stage protein engineering company that develops biotherapeutics to treat fibrosis and cancer, announced that the Phase 1a solid tumor trial exploring the safety and tolerability of AVID200, a first-in-class TGF-beta 1 & 3 selective inhibitor, administered as a monotherapy has fully enrolled.
Roche said that the phase 3 PEMPHIX trial of MabThera (rituximab) in moderate to severe pemphigus vulgaris (PV) met its primary endpoint at Week 52.
Pfizer Inc. (NYSE: PFE) announced today complete results from a Phase 3, 12-week, pivotal study (JADE MONO-1) in patients aged 12 and older with moderate to severe atopic dermatitis (AD).
Gilead Sciences and Galapagos NV announced that Week 52 data from the registrational Phase 3 FINCH 1 and FINCH 3 trials of filgotinib, an investigational, oral, selective JAK1 inhibitor, for the treatment of moderately-to-severely active rheumatoid arthritis (RA) are consistent with and support the efficacy, safety and tolerability profiles demonstrated in the Week 12 and 24 analyses presented earlier this year.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.